| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61f88efcda59d7062a4252ecf6886f58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c8cbbf2290b3f3a9988da29598baa2c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1e472e52510b9a0150fb8bb983e5c5a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-314
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-33 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48323
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6455 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2016-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7a22cba69a49f0957075acef961c0d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8925917a1ff03cb2a2f112eae84bb40a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7408b8f062f4cd65f24c8a3498501a64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a8b26bd196999f0688f38a8ed68d9e1 |
| publicationDate |
2017-02-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017051278-A1 |
| titleOfInvention |
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna |
| abstract |
Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10202602-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10076536-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10760078-B2 |
| priorityDate |
2011-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |